Bharat Biotech has officially released the final analysis of Phase-3 trial of Covaccine. According to this, the vaccine has been found to be 77.8 percent effective against the virus. Along with this, it is 65.2 percent effective against the delta variant of the corona virus.
At the same time, it has been found to be 93.4 percent effective against severe infection of corona virus. Covaccine has been found to be 78 percent effective in cases of mild and severe Kovid-19. It is 63% effective in asymptomatic cases. The company said in its results that 25,800 volunteers aged 18 to 98 years were included in the trial. The trial was conducted at 25 places across the country. After giving both doses to the volunteers involved in the trial, their health was monitored for about two weeks.
Emergency use was allowed in January
It is worth noting that the vaccines that are currently allowed to be used by people in the war against Corona in India include indigenously developed covaccine. Bharat Biotech handed over the trial data of Phase III of the Made in India Kovid-19 vaccine to DCGI some time back. Earlier, DCGI had given permission for emergency use of Covaccine in India in the month of January on the basis of Phase I and Phase II trial data.
More than 34 crore vaccine doses have been given in the country
At the same time, more than 34 crore vaccine doses have been given in India. According to the Union Health Ministry, 34,00,76,232 vaccine doses have been given till Friday morning, in which 27,94,54,091 people have been given the first dose while 6,06,22,141 both doses have been given. 8,92,46,934 people in the age group of 45 to 59 years have been given the first and 1,68,55,676 people have been given the second dose of corona vaccine. Whereas 6,83,55,887 people above 60 years of age have been given the first and 2,46,70,576 second doses.
Uttarakhand CM Tirath Singh Rawat submitted his resignation to the Governor, thanked PM Modi, Home Minister Shah and Nadda. Read 10 Big Things
Pregnant women can get the vaccine, CoWIN registration and walk-in allowed